TUCSON, Ariz., May 8, 2025 /PRNewswire/ -- The year 2025 marks a historic milestone for Critical Path Institute ® (C-Path), as the organization celebrates 20 years of transforming the landscape of ...

TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment ...

Global initiative to scale advanced therapeutic treatments to accelerate patient access worldwide. TUCSON, Ariz. and AMSTERDAM, March 26, 2026 /PRNewswire/ -- Critical Path Institute® (C-Path) today ...

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...

Tucson's Critical Path Institute recently got some good news - and some noteworthy recognition - when the U.S. Senate gave final approval to a budget reauthorization bill including the Food and Drug ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

Venture Partners at CU Boulder has announced the first recipients of a new translational funding program designed to advance promising, early-stage therapeutics with strong commercial potential. The ...

A generation ago, writing a piece like this about using artificial intelligence to develop genome-editing medicines would have sounded like a Star Trek plotline. But both fields have matured to the ...

University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery ...